Sat, Dec 27, 2014, 7:41 PM EST - U.S. Markets closed

Recent

% | $
Quotes you view appear here for quick access.

Nxstage Medical, Inc. Message Board

  • gcock10 gcock10 Dec 24, 2009 12:57 AM Flag

    HAVE YOU seen theMASSIVE INSIDER DUMPING?

    In the past few weeks, and last week?

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • Be careful of what you don't understand. It spreads fear and rumor. Virtually ALL Of that "inside trading is James Flynn who owns over 10% of the company (2,000,000) shares and has been selling since sept 09. Likely has to do w/ tax implications.
      If there were "insider" info he would not have been selling in Sept. Sit tight and remember what you bought the stock for.....

      • 1 Reply to cardiomd1
      • You would think traders/investors would understand the value of "FREEDOM"! But as always, they only value their own individual liberties. Whereas you and I we value other lives being improved on a daily basis, capitalism at its best. Even a fascist government will not deny you your dialysis, especially as it gets cheaper and more convenient. With all the cutting medicine/procedures available today, make no mistakes about this, the US government understand that the greatest advance has come from improved sanitary conditions, indoor plumbing, daily bath/soap/shampoo, fluoride tooth paste,toilet paper, garbage collection and now convenient and affordable home dialysis for those who need it.

    • Be careful of what you don't understand. It spreads fear and rumor. Virtually ALL Of that "inside trading is James Flynn who owns over 10% of the company (2,000,000) shares and has been selling since sept 09. Likely has to do w/ tax implications.
      If there were "insider" info he would not have been selling in Sept. Sit tight and remember what you bought the stock for.....

    • James Flynn has dumped approximately 350,000 shares or half his holdings. No other insiders have sold and I can't find any information on him. Good luck... with our federal government's new health care plan this stock will benefit tremendously. Self service health care and lowering the costs of regular procedures will be the focus of this new legislation and this stock is in the sweet spot.

      • 1 Reply to jbuck97224
      • James Flynn is a partner with Deerfield Managment and is not a company insider. Deerfield is dumping stock and the price is climbing some of the management there are kicking themselves for sure.
        Nice try to sew seeds of discord there Gcock....

        Deerfield Management cashes in on NxStage
        September 17, 2009 by MassDevice staffNew York hedge fund reaps a small windfall from its minority stake in the renal products maker, which is flirting with its best stock price in nearly 18 months; the fund also ups its stake in NeuroMetrix.


        A New York hedge fund specializing in medical-device and biotech plays has sold off 4.4 percent of its overall stake in NxStage Medical Inc.

        Deerfield Management, which manages more than $1 billion in assets through its various investment partnerships, sold a total of 226,638 NxStage shares in recent days, pocketing just more than $1.5 million in gross proceeds. A Deerfield offshore vehicle, Special Situations Fund International, made roughly two-thirds of the trades, and a domestic special situations fund accounted for the balance, according to security ownership documents.

        The dealing comes as stock in the Lawrence, Mass.-based portable dialysis equipment manufacturer is fetching some of its best prices in months. NxStage shares pushed past $7 each for the first time since February 2008 in mid-day trading Sept. 10, when Deerfield began selling, and has held above $6.40 during subsequent sessions. Through Sept. 16th's close, NxStage stock is up 248 percent since bottoming out at $1.92 a share May 6.

        Deerfield and its managing partner, James E. Flynn, have a penchant for buying NxStage on the cheap. Since the start of the year, Flynn purchased nearly 1.2 million of the company's shares, with the bulk of the buying occurring during the first quarter while the stock was bouncing between $2.13 and $3.99 a share. Deerfield's largest spree came last year during April, May and June, with Flynn doubling down amid a general selling spree after NxStage disappointed Wall Street despite meeting first-quarter revenue and net loss forecasts.

        Overall, Deerfield currently owns 4.9 million NxStage shares, equal to about 10.5 percent of the company's stock.

        The fund, meanwhile, recently boosted its stake in NeuroMetrix, snapping up 2.5 million shares at $2 each as part of a $19 million private placement completed Sept. 11. Deerfield now owns nearly 4.4 million shares, or 19.9 percent, of Waltham, Mass.-based NeuroMetrix, which is developing nerve and spinal cord testing and treatment equipment.

    • my_other_ride_is_your_gf my_other_ride_is_your_gf Dec 24, 2009 9:43 AM Flag

      ROFLMAO You are a funny man!

 
NXTM
18.19-0.20(-1.09%)Dec 26 4:00 PMEST

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.
Prothena Corporation plc
NASDAQFri, Dec 26, 2014 4:00 PM EST
Fluor Corporation
NYSEFri, Dec 26, 2014 4:03 PM EST